The world of diagnostics is evolving, and Crownlands is at the forefront of this revolution. While nasopharyngeal swabs are commonly associated with COVID-19 testing, Crownlands is taking a unique approach by harnessing the power of the olfactory epithelium for a different purpose: understanding the molecular state of the brain. This innovative biotech startup is not just about developing specialized swabs; it's about unlocking the secrets hidden within the nasal cavity, which could potentially transform drug discovery in neurodegeneration.
A New Perspective on Brain Health
The olfactory epithelium, located in a cavity high in the nose, is a fascinating tissue. It shares remarkable similarities with neurons in the brain, particularly in individuals with Alzheimer's disease. For instance, olfactory tissue from Alzheimer's patients exhibits the same amyloid-β aggregates found in the brain. However, what sets olfactory neurons apart is their ability to regenerate, offering a unique opportunity for longitudinal sampling.
"They're constantly turning over through life, which means that... we can go back and sample longitudinally," explains Crownlands cofounder and head of discovery, Kevin Zhu. This capability is a game-changer, as it allows researchers to track changes over time and gain insights into the progression of neurodegenerative diseases.
The Power of Longitudinal Data
Crownlands' researchers have developed a specialized swab to access the olfactory epithelium more reliably. By collecting and sequencing samples from 202 individuals, including healthy volunteers and those diagnosed with Alzheimer's or Parkinson's disease, they have created a transcriptomic atlas of the tissue. This dataset comprises single-cell transcriptomes from 4 million cells, providing a wealth of information for researchers and the public alike.
The preprint study, which has not been peer-reviewed, reveals that olfactory neurons offer a closer match to gene expression patterns in the brain compared to other clinically accessible samples like cerebrospinal fluid or blood. This finding is particularly intriguing, as it suggests that the olfactory epithelium may provide a more accurate representation of brain health.
Unlocking the Potential of AI
Crownlands' business model revolves around building large, longitudinal datasets. By analyzing these datasets with artificial intelligence, the company aims to offer insights into risk factors for neurodegenerative diseases, biomarkers for their progression, and ways to optimize clinical trials. This approach could revolutionize the way we understand and treat these complex conditions.
"Our business model is building very large, longitudinal datasets," says Crownlands cofounder and CEO, Nate Dalva. This ambitious goal has already attracted significant investment from venture capital firms, including Caffeinated Capital, First Round Capital Holdings, and Scribble Ventures.
The Future of Brain Health
Crownlands' innovative approach to brain health diagnostics is a testament to the power of noninvasive patient data collection. By harnessing the potential of the olfactory epithelium, the company is paving the way for a new era of drug discovery in neurodegeneration. As the field of diagnostics continues to evolve, Crownlands is setting a new standard for understanding the molecular state of the brain and its impact on human health.
